Abstract 512
Background
The aim of this study was to investigate the role of circulating tumor cells (CTCs) in assessing and predicting of pathological response to preoperative CRT of rectal cancer.
Methods
Sixty-seven patients (average age: 55; male/female: 35/32) with T3-4 and/or N+ rectal cancer were enrolled. All patients received preoperative CRT followed by radical surgery after 6-8 weeks. Blood samples were obtained from patients before and after CRT. CTCs were detected by use of a high-performance size-based micro-fluidic device, which exploited numerous filtered micro-channels in it to enrich the large-sized target tumor cells from whole blood. The pathological results after surgery was evaluated according to tumor regression grade (TRG) classification. The association between CTC counts and the pathological tumor response was analyzed.
Results
CTC counts before CRT were significantly higher than those after CRT (41.24 ± 18.45/5mL vs. 9.7 ± 8.9/5mL, P
Conclusions
Circulating tumor cells are promising markers to predict tumor response after preoperative CRT for rectal cancer.
Clinical trial identification
Legal entity responsible for the study
Fudan University Shanghai Cancer Center
Funding
The National Natural Science Foundation of China
Disclosure
W. Sun, Z. Zhang: I identify that no financial interst in products or processes involved in their research.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract